webinar register page

Webinar banner
BIOBETTERS ACADAMY - Clinical experience with biobetters in IBD
Biosimilars are increasingly used to treat patients with IMIDs. Biobetters have changed the way oncology patients are treated. Biobetters may be associated with improvements in clinical outcomes and drug pharmacology. The first anti-TNF biobetter was recently approved for IBD. What is a biobetter? What is the current level of evidence in IBD? What are the indications of biobetters in IBD? These questions will be answered during this interactive webinar.

Silvio Danese, Italy
Axel Dignass, Germany

When to initiate? Clinical cases 15’
Benedicte Caron, France

When to switch? Clinical cases 15’
Laurent Peyrin-Biroulet, France

Experience with biobetters in case of previous IV Infliximab failure 15’
Mathurin Fumery, France

Q&A 10’

Jun 30, 2022 01:00 PM in Rome

* Required information